Kasten, Inc. functions as a biopharmaceutical enterprise, concentrating its efforts on identifying, advancing, and commercializing medicinal therapies intended to address and avert critical ailments prevalent in both clinical and community environments. The company primarily aims to provide effective options for individuals grappling with antimicrobial resistance, striving to make vital pharmaceutical products accessible. Leveraging its Site Specific Penetration Technology (SSPT™), acquired through its integration with DAKOTA Life Sciences, Kasten develops a range of topical antibiotics and antifungals, including those targeting resistant bacterial infections like MRSA. Established in 1986, the firm is headquartered in Sioux Falls, South Dakota.